BCG lymphadenopathy detected in a BCG-vaccinated infant

Barouni, A. S.; Augusto, Claudio José; Queiroz, M V N P; Lopes, Míriam Teresa Paz; Zanini, Marcos Santos; Salas, Carlos

doi:10.1590/s0100-879x2004000500011

Cited by 12 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCG lymphadenitis presented at the age of 2-6 months in 64.47% of our patients, although there can be a delay up to 24 months, as found in this study, and the same has been reported by Barouni et al [21]. Several factors such as age of the child, technique of vaccination, the BCG strain, and the dose, potency, viability, and immunogenicity of the vaccine are implicated in the pathogenesis of lymphadenitis [20].…”

Section: Discussionsupporting

confidence: 86%

“…As in our series, Ritz et al [12] and Barouni et al [21] reported that a multidrug-resistant mycobacterial strain was isolated from a 24-month-old child with BCG lymphadenopathy who had received the Brazilian BCG strain. As in our series, Ritz et al [12] and Barouni et al [21] reported that a multidrug-resistant mycobacterial strain was isolated from a 24-month-old child with BCG lymphadenopathy who had received the Brazilian BCG strain.…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Post-Bacillus Calmette-Guérin lymphadenitis in Egyptian children

Hassan¹,

Aly²,

Kandil³

et al. 2012

Annals of Pediatric Surgery

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 65%

Post-Bacillus Calmette-Guérin lymphadenitis in Egyptian children

Hassan¹,

Aly²,

Kandil³

et al. 2012

Annals of Pediatric Surgery

View full text Add to dashboard Cite

“…There is evidence that BCG may persist for many years in humans [37,[47][48][49][50][51][52] and together with the observed waning of immune responses to BCG through childhood [36]; this may represent gradual clearance of bacilli and associated T cells.…”

Section: Discussionmentioning

confidence: 99%

Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis

Kaveh

García-Pelayo

Hogarth

2014

Vaccine

View full text Add to dashboard Cite

Tuberculosis (TB) remains one of the most important infectious diseases of man and animals, and the only available vaccine (BCG) requires urgent replacement or improvement. To facilitate this, the protective mechanisms induced by BCG require further understanding. As a live attenuated vaccine, persistence of BCG bacilli in the host may be a crucial mechanism. We have investigated the long term persistence of BCG following vaccination and the influence on the induced immune response and protection, using an established murine model. We sought to establish whether previously identified BCG-specific CD4 TEM cells represent genuine long-lived memory cells of a relatively high frequency, or are a consequence of continual priming by chronically persistent BCG vaccine bacilli. By clearing persistent bacilli, we have compared immune responses (spleen and lung CD4: cytokine producing T effector/TEM; TCR-specific) and BCG-induced protection, in the presence and absence of these persisting vaccine bacilli. Viable BCG bacilli persisted for at least 16 months post-vaccination, associated with specific CD4 T effector/TEM and tetramer-specific responses. Clearing these bacilli abrogated all BCG-specific CD4 T cells whilst only reducing protection by 1log10. BCG may induce two additive mechanisms of immunity: (i) dependant on the presence of viable bacilli and TEM; and (ii) independent of these factors. These data have crucial implications on the rational generation of replacement TB vaccines, and the interpretation of BCG induced immunity in animal models.

show abstract

“…Isoniazid resistance was concerning, although we could not ascertain the batch or the strain that the patient received. Isoniazid-resistant BCG lymphadenitis has been rarely described in case reports (14,15).…”

Section: Discussionmentioning

confidence: 99%

Mycobacterial Brain Tuberculomas due to Bacille Calmette-Guérin Intravesical Chemotherapy for Bladder Cancer: A Case Report and Literature Review

Golub

Malhotra

Patel

2011

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

Bacille Calmette-Guérin (BCG) immunotherapy is widely used for the treatment of superficial bladder cancer. The authors believe that the present report is one of the first to document cerebral BCG tuberculoma in a 73-year-old immunocompetent man, three years after intra-vesical BCG immunotherapy. His workup revealed no identifiable extracranial source. He responded well to treatment with rifampin, ethambutol and moxifloxacin.Patients undergoing intravesical BCG therapy should be closely monitored for the development of this complication. Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections.

show abstract

BCG lymphadenopathy detected in a BCG-vaccinated infant

Cited by 12 publications

References 8 publications

Post-Bacillus Calmette-Guérin lymphadenitis in Egyptian children

Post-Bacillus Calmette-Guérin lymphadenitis in Egyptian children

Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis

Mycobacterial Brain Tuberculomas due to Bacille Calmette-Guérin Intravesical Chemotherapy for Bladder Cancer: A Case Report and Literature Review

Contact Info

Product

Resources

About